Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 39

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 39
---
 enough available authorized shares of common stock under our Amended and Restated Certificate of Incorporation to accommodate the number of shares then reserved under the Amended 2023 Plan. We will have enough available authorized shares to accommodate the number of shares reserved under the Amended 2023 Plan if we either (i) obtain approval of Proposal No. 2 (the Charter Amendment Proposal) and file the Certificate of Amendment to our Amended and Restated Certificate of Incorporation contemplated thereby or (ii) obtain approval of Proposal No. 4 (the Reverse Stock Split Proposal) and file the Certificate of Amendment to our Amended and Restated Certificate of Incorporation contemplated thereby (at a reverse stock split ratio at or greater than 1 -for-4.5) when we are permitted to under the Purchase Agreements. Under the terms of the Purchase Agreements, we are prohibited from completing a reverse stock split prior to September 6, 2025 unless we are expressly required to effect a reverse split as a result of changes in applicable laws effected after the closing of the Private Placement related to the listing requirements of the trading market (currently Nasdaq) or we obtain a waiver from the investors who purchased at least 50.1% of the Shares and Pre -FundedWarrants sold in the Private Placement. As of the date hereof, we are not aware of any such changes in applicable law. As of April 11, 2025, a total of 2,550,548shares of our common stock remain available for issuance under the 2023 Plan and restricted stock units representing the contingent right to receive an aggregate of 670,469shares of our common stock were outstanding. As of April 11, 2025, a total of 1,778,983shares of our common stock have been issued upon the exercise of options and the vesting of restricted stock units granted under the 2023 Plan. As of April 11, 2025, the equity overhang, represented by (a) the sum of all outstanding restricted stock units and other stock -basedawards under all Company equity plans, plus the number of shares available for issuance pursuant to future awards under the 2023 Plan as a percentage of (b) the sum of (i) the number of shares of our common stock outstanding as of April 11, 2025, plus (ii) the number of shares described in clause (a) above, 22 was 12.5%. If the Amended 202